The Indian pharmaceutical company ACME Formulation Pvt. Ltd. have achieved WHO prequalification for their Misoprostol 200µg tablet product, with technical assistance provided by Concept Foundation and supported by UNCoLSC and the Packard Foundation.
This newly prequalified product further expands the choice of quality-assured oxytocics that are available for procurement to help alleviate the burden of post-partum haemorrhage (PPH) in lower- and middle-income countries (LMICs). Misoprostol is recommended by the WHO for use in prevention and treatment of PPH in situations where oxytocin cannot be provided. More information on misoprostol and WHO prequalification can be found on our Resources page.